Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial-Reference-Cited by-同舟云学术

Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial

Published:2023-11 Issue:11 Volume:5 Page:e660-e669
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Distler Oliver,Allanore Yannick,Denton Christopher P,Kuwana Masataka,Matucci-Cerinic Marco,Pope Janet E,Atsumi Tatsuya,Bečvář Radim,Czirják László,Hachulla Eric,Ishii Tomonori,Ishikawa Osamu,Johnson Sindhu R,De Langhe Ellen,Stagnaro Chiara,Riccieri Valeria,Schiopu Elena,Silver Richard M,Smith Vanessa,Steen Virginia,Stevens Wendy,Szücs Gabriella,Truchetet Marie-Elise,Wosnitza Melanie,Laapas Kaisa,Kramer Frank,Khanna Dinesh

Funder

Bayer

Merck Sharp and Dohme United Kingdom

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference30 articles.

1. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis;Khanna;J Scleroderma Relat Disord,2017

2. Current and future outlook on disease modification and defining low disease activity in systemic sclerosis;Nagaraja;Arthritis Rheumatol,2020

3. Systemic sclerosis;Denton;Lancet,2017

4. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study;Jaeger;PLoS One,2016

5. BSR and BHPR guideline for the treatment of systemic sclerosis;Denton;Rheumatology (Oxford),2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: From Bedside to Bench and Back Again;International Journal of Molecular Sciences;2024-04-26

2. Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis;Rheumatology;2024-03-09

3. Riociguat in systemic sclerosis: challenges in crossing the bridge from bench to bedside;The Lancet Rheumatology;2023-11